Advertisement

Discussion of “Risk management decisions in women with BRCA1 and BRCA2 mutations”

Published:February 15, 2018DOI:https://doi.org/10.1016/j.amjsurg.2017.11.067

      Highlights

      • This was an analysis of treatment decisions based on genetic mutations in breast cancer.
      • The study was a retrospective review.
      • There was a higher than expected percentage of risk reduction surgery in the mutation of unknown clinical significance.
      • Patients in the Pacific Northwest chose radiographic surveillance over surgery more than other regions.
      • Surgeons must help patients understand the difference between pathogenic mutations and variants of unknown significance.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      Linked Article